542 related articles for article (PubMed ID: 18836475)
1. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
2. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
3. NKG2D ligands: key targets of the immune response.
González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
[TBL] [Abstract][Full Text] [Related]
4. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
5. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
6. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
[TBL] [Abstract][Full Text] [Related]
7. NK cells and cancer immunosurveillance.
Waldhauer I; Steinle A
Oncogene; 2008 Oct; 27(45):5932-43. PubMed ID: 18836474
[TBL] [Abstract][Full Text] [Related]
8. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
10. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
Zhang C; Zhang J; Wei H; Tian Z
Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
[TBL] [Abstract][Full Text] [Related]
11. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V; Smythe K; Dai Z; Spies T
Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.
Zwirner NW; Fuertes MB; Girart MV; Domaica CI; Rossi LE
Cytokine Growth Factor Rev; 2007; 18(1-2):159-70. PubMed ID: 17324607
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell recognition by the NK cell activating receptor NKG2D.
Bryceson YT; Ljunggren HG
Eur J Immunol; 2008 Nov; 38(11):2957-61. PubMed ID: 18979516
[TBL] [Abstract][Full Text] [Related]
14. Exosomes and the MICA-NKG2D system in cancer.
Clayton A; Tabi Z
Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
[TBL] [Abstract][Full Text] [Related]
15. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
16. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
17. The NKG2D receptor: sensing stressed cells.
López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
[TBL] [Abstract][Full Text] [Related]
18. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
19. Innate immune recognition and suppression of tumors.
Hayakawa Y; Smyth MJ
Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
[TBL] [Abstract][Full Text] [Related]
20. NKG2D and cytotoxic effector function in tumor immune surveillance.
Hayakawa Y; Smyth MJ
Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
